Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete
I'm PortAI, I can summarize articles.
Avalo Therapeutics reported a Q3 net loss of $30.63 million, missing analyst expectations of $18.75 million. Operating expenses increased due to costs from the Phase 2 LOTUS trial, which has completed enrollment with data expected by mid-2026. Avalo anticipates cash reserves to sustain operations until 2028. The average analyst rating for Avalo shares is "buy," with a median 12-month price target of $35.00, representing a 53% upside from its recent closing price of $16.45.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments